With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.
The pharmaceutical industry is back. Fueled by the launch of expensive, new biotech medicines, rising prices for both branded and generic drugs and a recent slowdown in branded-drug patent expirations and generic competition, the U.S. pharmaceutical market is staging a remarkable resurgence.
The holiday season is the battery category’s best friend. A shift in the consumer electronics industry to built-in rechargeable batteries and the growth of do-it-all smartphones that replace many battery-operated devices has left the category in a slump.
Australian Dream is one of those hot external analgesic products that has been growing by greater than 20% across all channels. Drug Store News had an opportunity to dig a little deeper regarding the Nature s Health Connection s Australian Dream product with David Biernbaum of David Biernbaum and Assoc., who represents the product.
External analgesics is a category replete with growth brands with a base of $497.8 million across total U.S. multi-outlets, and more than 8.1% in growth for the 52 weeks ended Sept. 7, according to IRI data.
After a recent spike in the prices charged for some generic drugs led to outcries from pharmacists, patient advocates and federal lawmakers, a report issued last month suggests that drug costs can be controlled if the Food and Drug Administration changes the way it handles reviews and approvals.
Mscripts has built a comprehensive digital pharmacy platform designed to improve adherence and compliance among patients. “Traditionally, we’ve focused on two-way text messaging and mobile applications,” Mark Cullen, Mscripts CEO, told Drug Store News.